These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 15170907)
41. [10 years of treatment with TNF inhibitors--are we on the safe side?]. Zink A; Schneider M Z Rheumatol; 2010 Nov; 69(9):772-3. PubMed ID: 21063824 [No Abstract] [Full Text] [Related]
42. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center]. de Oliveira SK; de Almeida RG; Fonseca AR; Rodrigues MC; Sztajnbok F; Diniz C Acta Reumatol Port; 2007; 32(2):139-50. PubMed ID: 17572652 [TBL] [Abstract][Full Text] [Related]
43. Introduction. Cantini F Expert Opin Drug Saf; 2016 Dec; 15(sup1):1. PubMed ID: 27924647 [No Abstract] [Full Text] [Related]
44. Anti-tumor necrosis factor therapies in immune-mediated rheumatic diseases. Other observations from the clinic. Russell AS; Rosenbaum JT J Rheumatol Suppl; 2010 May; 85():53-62. PubMed ID: 20436165 [TBL] [Abstract][Full Text] [Related]
45. Anti-cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis treated with anti-tumour necrosis factor agents. Russell AS; Maksymowych WP; de Silva M Ann Rheum Dis; 2005 Dec; 64(12):1807. PubMed ID: 16284357 [No Abstract] [Full Text] [Related]
46. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. Vassilopoulos D; Stamoulis N; Hadziyannis E; Archimandritis AJ J Rheumatol; 2008 Jul; 35(7):1271-6. PubMed ID: 18381793 [TBL] [Abstract][Full Text] [Related]
47. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents. Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227 [No Abstract] [Full Text] [Related]
48. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559 [TBL] [Abstract][Full Text] [Related]
49. Completion rate and compliance of anti-tuberculosis chemoprophylaxis in patients with rheumatic disease receiving tumor necrosis factor antagonists. Ideguchi H; Ohno S; Takase K; Kirino Y; Suda A; Ihata A; Ueda A; Takeno M; Nagaoka S; Ishigatsubo Y Clin Exp Rheumatol; 2010; 28(2):294-5. PubMed ID: 20483059 [No Abstract] [Full Text] [Related]
50. New cytokine targets in inflammatory rheumatic diseases. Connell L; McInnes IB Best Pract Res Clin Rheumatol; 2006 Oct; 20(5):865-78. PubMed ID: 16980211 [TBL] [Abstract][Full Text] [Related]
51. Should anti-tumor necrosis factor-alpha be the first therapy for rheumatoid vasculitis? Garcia-Porrua C; Gonzalez-Gay MA; Quevedo V J Rheumatol; 2006 Feb; 33(2):433; author reply 433-4. PubMed ID: 16465676 [No Abstract] [Full Text] [Related]
53. The application of infliximab (Remicade), a chimeric monoclonal antibody, in the treatment of rheumatic diseases. Kalden JR Isr Med Assoc J; 2000 Dec; 2 Suppl():11-2. PubMed ID: 11344856 [No Abstract] [Full Text] [Related]